Mario Rovirosa – CEO, Ferrer
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
Founded in 1959, Ferrer is a Spanish multinational privately-held pharmaceutical company headquartered in Barcelona with a presence in over 90 countries. They operate in the pharmaceutical, health, fine chemicals (API), and food sectors. The company has expertise in the fields of cardiology, central nervous system, dermatology, gastroenterology, metabolism, oncology, musculoskeletal system, paediatrics, pain management, and respiratory.
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
Alejandro Mora, Ferrer’s country manager for Central America & Caribbean, discusses the complexity of the region’s healthcare systems, the company’s strategy to compete against local players, and the importance for…
Xavier Rams, General Director at Ferrer Mexico, explains the importance of aligning corporate strategy to public healthcare goals in order to succeed in the dynamic Mexican environment and showcases the…
CPH Pharma was the oldest running pharmaceutical company in Portugal until its acquisition by Grupo Ferrer in 2008. Since then, the company has continued to thrive in the marketplace despite…
Our business model is new in the Chilean market and enables us with great flexibility and allows us to focus on demand generation. For Ferrer this is a great window…
In the second part of a two-part interview, Generika Philippines co-founders, Teodoro Ferrer and Julien Bello, go on to discuss the future of generic medicines in the Philippines, the compnay’s…
In part one of a two-part interview, Generika Philippines co-founders Teodoro Ferrer and Julien Bello discuss what led them to start the company, the changing mentality among the Filipino population…
Carlos Rubió, executive president of Laboratorios Rubió, gives an overview of the company’s early years and his priorities now to make the company a larger player on the international scene.…
Jordi Naval, CEO of Biocat, describes the evolution of the BioRegion of Catalonia as an increasingly relevant biotechnology hub in Spain and Europe. Naval also elaborates on the role of…
Gijs Jochems, general manager of Promega Biotech Iberica, a leading molecular biology solutions provider, speaks about the company’s business transformation to collaborate with diverse areas of the private sector. Jochems…
Joachim Teubner, general manager of Aristo Pharma Iberia, a generics player, highlights the strategy that has helped the company realize rapid growth during a time in which the Spanish generic…
Spain’s biotech scene is on the rise. In 2016 alone, the nation had a total of 651 biotech companies, with a total of 33 commencing operations in 2017. Despite these…
Miguel Valdés, director of Fedifar, the Spanish wholesaler federation, highlights the challenges impacting the local wholesaler network and the unique nature of Spanish wholesaler ecosystem, with the majority of players…
Cédric Ertlé, general director of Laboratoires Expanscience Iberia, talks about his strategy to turn around the affiliate’s dermo cosmetic range in what is a shrinking Spanish market and his goal…
Joël Jean-Mairet, general partner of Ysios Capital, discusses the major trends impacting the venture capital ecosystem in the life sciences sector and the complexity of attracting new investors to the…
A new study shows that the Spanish population is unclear on the meaning of self-care and often seeks a second opinion online post-visiting the doctor. Although 82.7% of Spaniards…
Andreu Mas-Colell, former minister of finance for Catalonia and president of the Barcelona Institute of Science and Technology (BIST), discusses the mission and activities of the institution as a driver…
According to a survey carried out by the Spanish Foundation for Science and Technology (FECYT) over half of the Spanish population believe Pseudo-therapies to be of real value. “Public…
Manuel Ramos Ortega, chairman of Labiana, a Spanish CDMO, highlights his strategy to create company stability and discusses the major trends in the manufacturing world of human medicines. Furthermore, he…
See our Cookie Privacy Policy Here
